Inhibition of oncogenic MAPK signaling in melanoma triggers SOX2-dependent adaptive drug resistance programs. (July 2016) - Flueckiger, S.; Aloia, A.; Frischknecht, L.; Tuozzo, A.; Croci, D.; Shakhova, O.; Britschgi, C.; Levesque, M.P.; Dummer, R.; Krek, W.